Richard Marlink, MD, principal investigator for the Enhancing Care Initiative, is executive director of the Harvard AIDS Institute and senior research director in the Department of Immunology and Infectious Diseases at the Harvard School of Public Health. Representing the largest concentration of AIDS researchers nationally, the Harvard AIDS Institute is a premier nongovernmental organization dedicated to promoting research to curb the HIV epidemic and to helping those most affected by the epidemic nationally and internationally.
Marlink's early research efforts involved collaborative trials of new anticancer agents, followed by similar trials for antivirals used against HIV infection. Following his participation on the team that first identified HIV-2, the second AIDS virus, Marlink became involved in laboratory research at the Harvard School of Public Health and in epidemiologic and clinical studies in Senegal, West Africa. In addition, in Senegal he helped coordinate studies to determine the clinical and biologic characteristics of both HIV-1 and HIV-2.
Along with serving in various teaching and clinical capacities, Marlink directs an effort at the Harvard School of Public Health that provides laboratory training and backup to investigators in the United States, Botswana, Mexico, Senegal, and Thailand who are working on research involving injection drug users and other populations at risk for HIV infection.